All In Biotech

Drug Trial Radar · NCT06397508

Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants

A Randomized, Open-Label, 3-Period, Single-Dose, Cross-Over Study in Healthy Participants to Assess the Relative Bioavailability of AGMB-129 Given as Tablet Formulation Versus the Capsule Reference Formulation and to Assess the Effect of Food on Tablet Formulation

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Apr 2, 2024

Primary completion

May 8, 2024

Study completion May 13, 2024

Sponsor

Lead sponsor
Agomab Spain S.L.Industry
Sponsor type
Industry
First posted
May 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, single-dose, randomized, 3-period cross-over, Phase 1 study in healthy adult participants to assess the BA of AGMB-129 tablet formulation relative to that of the reference capsule formulation and to assess the effect of food on the BA of a single oral dose of the AGMB-129 tablet formulation. A total of 24 participants will be enrolled. Participants will be randomized to 1 of 6 intervention sequences (Williams design) according to a 6-sequence, 3-period design. In 3 sequential intervention periods, each participant will receive 3 study interventions, 1 in each intervention period. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.

Conditions

  • Healthy Volunteers

Interventions

  • AGMB-129Drug

    Each participant will receive 3 study interventions, 1 in each intervention period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax for AGMB-129Time frame: From baseline to Day 3
  2. Cmax for MET-158Time frame: From baseline to Day 3
  3. Cmax for MET-154Time frame: From baseline to Day 3
  4. AUC0-t for AGMB-129Time frame: From baseline to Day 3
  5. AUC0-t for MET-158Time frame: From baseline to Day 3
  6. AUC0-t for MET-154Time frame: From baseline to Day 3
  7. AUC0-∞ for AGMB-447Time frame: From baseline to Day 3
  8. AUC0-∞ for MET-158Time frame: From baseline to Day 3
  9. AUC0-∞ for MET-154Time frame: From baseline to Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Belgium

    Edegem, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.